Lone Star Value Management Lowers stake in Dipexium Pharmaceuticals Inc (DPRX)

Dipexium Pharmaceuticals Inc (DPRX) : Lone Star Value Management reduced its stake in Dipexium Pharmaceuticals Inc by 5.24% during the most recent quarter end. The investment management company now holds a total of 217,805 shares of Dipexium Pharmaceuticals Inc which is valued at $2.5 Million after selling 12,036 shares in Dipexium Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on May 13, 2016.Dipexium Pharmaceuticals Inc makes up approximately 5.21% of Lone Star Value Management’s portfolio.

Other Hedge Funds, Including , Opus Point Partners Management sold out all of its stake in DPRX during the most recent quarter. The investment firm sold 25,000 shares of DPRX which is valued $284,750.1492 Capital Management reduced its stake in DPRX by selling 1,185 shares or 3.4% in the most recent quarter. The Hedge Fund company now holds 33,634 shares of DPRX which is valued at $383,091. Dipexium Pharmaceuticals Inc makes up approx 0.33% of 1492 Capital Management’s portfolio.Blackrock Fund Advisors reduced its stake in DPRX by selling 852 shares or 6.1% in the most recent quarter. The Hedge Fund company now holds 13,106 shares of DPRX which is valued at $149,277. Financial Architects Inc added DPRX to its portfolio by purchasing 350 company shares during the most recent quarter which is valued at $3,987.Russell Frank Co boosted its stake in DPRX in the latest quarter, The investment management firm added 21,954 additional shares and now holds a total of 104,369 shares of Dipexium Pharmaceuticals Inc which is valued at $1.4 Million.

Dipexium Pharmaceuticals Inc closed down -0.26 points or -2.21% at $11.5 with 63,920 shares getting traded on Wednesday. Post opening the session at $11.56, the shares hit an intraday low of $11.3601 and an intraday high of $11.56 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Dipexium Pharmaceuticals Inc. is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex a topical antibiotic. Locilex is a chemically synthesized 22-amino acid peptide isolated from the skin of the African Clawed Frog. Its mechanism of action kills microbial targets by disrupting the bacterial cell membrane. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI). Locilex affects only the area to which it is applied. Locilex has demonstrated statistical non-inferiority to a systemic antibiotic in a clinical study in patients with Mild or Moderate DFI. It has conducted microbiology studies that highlight the sensitivity of resistant bacteria including methicillin-resistant staphylococcour aureour (MRSA) vancomycin-resistant enterococcour (VRE) extended-spectrum b-lactamase (ESBL) and multi-drug resistant (or MDR) bacteria to pexiganan the active pharmaceutical ingredient (API) in Locilex.

Leave a Reply

Dipexium Pharmaceuticals Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Dipexium Pharmaceuticals Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.